KRAS and colorectal carcinoma: It either involves the amplification of CRC cells carrying an activated KRAS mutation, which constitute a minority clone within a heterogeneous group of wild type KRAS cells (Misale et al., 2012), or the development of cetuximab resistance through microenvironmental changes (Woolston et al., 2019).